Celldex Therapeutics (NASDAQ:CLDX) Insider Richard Wright Sells 49,298 Shares

Celldex Therapeutics insider Richard Wright sold 49,298 shares at $24 each, totaling $1,183,152. Post-sale, he owns 20,833 shares, a 70.29% decrease in his position. The sale was disclosed in an SEC filing. Celldex's stock rose 1.8% to $26, with a market cap of $1.73 billion. Analysts have mixed ratings, with a moderate buy consensus and a $43.80 average target price.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) insider Richard Wright sold 49,298 shares of the company's stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the sale, the insider owned 20,833 shares of the company's stock, valued at $499,992. The trade was a 70.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Get Celldex Therapeutics alerts:

Celldex Therapeutics Trading Up 1.8%

Shares of NASDAQ:CLDX traded up $0.45 during midday trading on Monday, hitting $26.00. The company had a trading volume of 1,183,718 shares, compared to its average volume of 1,018,647. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $29.05. The firm has a fifty day simple moving average of $25.56 and a 200 day simple moving average of $22.88. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -8.64 and a beta of 1.36.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. Equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on CLDX shares. Canaccord Genuity Group reissued a "buy" rating and set a $62.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Barclays reduced their price target on shares of Celldex Therapeutics from $25.00 to $21.00 and set an "underweight" rating on the stock in a research report on Tuesday, November 11th. Wells Fargo & Company lowered their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a research report on Wednesday, August 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Finally, Mizuho began coverage on Celldex Therapeutics in a report on Tuesday, October 21st. They issued an "outperform" rating and a $48.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $43.80.

Check Out Our Latest Report on Celldex Therapeutics

Hedge Funds Weigh In On Celldex Therapeutics

A number of large investors have recently added to or reduced their stakes in CLDX. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Celldex Therapeutics in the first quarter valued at about $269,000. GSA Capital Partners LLP acquired a new stake in Celldex Therapeutics in the 1st quarter valued at approximately $1,131,000. Vanguard Group Inc. lifted its stake in Celldex Therapeutics by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company's stock valued at $70,757,000 after acquiring an additional 16,440 shares in the last quarter. Deutsche Bank AG boosted its position in Celldex Therapeutics by 13.8% during the 1st quarter. Deutsche Bank AG now owns 138,289 shares of the biopharmaceutical company's stock worth $2,510,000 after acquiring an additional 16,788 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Celldex Therapeutics by 24.6% during the 1st quarter. Invesco Ltd. now owns 52,443 shares of the biopharmaceutical company's stock worth $952,000 after acquiring an additional 10,342 shares during the last quarter.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Should You Invest $1,000 in Celldex Therapeutics Right Now?

Before you consider Celldex Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.

While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here